Evelyn Partners Investment Management Europe Ltd Purchases Shares of 21,991 Astrazeneca Plc $AZN

Evelyn Partners Investment Management Europe Ltd purchased a new position in Astrazeneca Plc (NYSE:AZN) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 21,991 shares of the company’s stock, valued at approximately $4,273,000. Astrazeneca accounts for about 1.5% of Evelyn Partners Investment Management Europe Ltd’s investment portfolio, making the stock its 19th biggest position.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Triumph Capital Management bought a new stake in Astrazeneca during the third quarter valued at $25,000. MV Capital Management Inc. purchased a new position in Astrazeneca during the fourth quarter worth about $26,000. Mascoma Wealth Management LLC bought a new position in Astrazeneca in the 1st quarter worth about $26,000. Bangor Savings Bank increased its stake in Astrazeneca by 102.7% in the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after acquiring an additional 154 shares during the last quarter. Finally, Eagle Bay Advisors LLC purchased a new stake in shares of Astrazeneca in the 4th quarter valued at about $30,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on AZN. Sanford C. Bernstein reiterated a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. Barclays restated a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. HSBC downgraded shares of Astrazeneca from a “buy” rating to a “hold” rating in a research note on Monday, July 13th. Morgan Stanley reiterated an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a research note on Friday, June 26th. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $211.00.

Astrazeneca News Roundup

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: Profit beat and outlook maintained: Second-quarter earnings were $2.63 per share, well above the $2.10 analyst consensus. AstraZeneca also backed its 2026 forecasts, helping ease concerns about longer-term growth. AstraZeneca beats second-quarter profit expectations, holds outlook
• Positive Sentiment: Oncology and rare-disease demand remained strong: Growth from cancer, heart-disease and rare-disease therapies helped offset weaker sales in other products and increasing generic competition. First-half revenue rose 9% to $30.7 billion, or 6% at constant exchange rates. AZN Q2 Earnings and Sales Beat, Key Drugs Offset Generic Pressure
• Neutral Sentiment: Revenue slightly missed expectations: Quarterly revenue increased 6.4% year over year to $15.38 billion, narrowly below the $15.44 billion analyst estimate. Management is also navigating weaker conditions in China and the loss of exclusivity for certain products. AstraZeneca Q2 2026 Earnings Call Highlights
• Negative Sentiment: Pipeline setback: Ultomiris failed to meet the main goal in a late-stage trial involving a blood-vessel complication after stem-cell transplantation. The result adds to recent concerns about AstraZeneca’s development pipeline, although the company’s established portfolio supported the quarter. AstraZeneca’s rare disease drug misses main goal in late-stage trial
• Negative Sentiment: U.S. pricing pressure remains a risk: AstraZeneca is adjusting pricing strategies for new medicines in response to the Trump administration’s most-favoured-nation policy, which could constrain future pricing and margins in the U.S. AstraZeneca drug prices evolving in response to Trump policy

Astrazeneca Trading Up 0.4%

Shares of AZN stock opened at $170.02 on Tuesday. The business has a 50-day moving average price of $180.27 and a two-hundred day moving average price of $187.99. Astrazeneca Plc has a 12-month low of $142.98 and a 12-month high of $212.71. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. The firm has a market cap of $263.68 billion, a P/E ratio of 25.53, a price-to-earnings-growth ratio of 1.38 and a beta of 0.24.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings data on Monday, July 27th. The company reported $2.63 EPS for the quarter, beating the consensus estimate of $2.50 by $0.13. The firm had revenue of $15.38 billion for the quarter, compared to analyst estimates of $15.44 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The company’s revenue was up 6.4% on a year-over-year basis. During the same period in the prior year, the company earned $2.17 EPS. Equities analysts anticipate that Astrazeneca Plc will post 10.22 EPS for the current fiscal year.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.